Experimental Cholesterol Drug Results Called “Game Changing”
By Ann J. Curley, CNN Medical Assignment Manager
(CNN) — A new, experimental cholesterol-fighting drug is creating quite a buzz among researchers and other experts, prompting some to use words such as “dramatic,” “breakthrough” and “game changing,” to describe early-stage clinical trial results.
If these initial results pan out in larger trials, the drug could prove to be more effective than statins, the widely prescribed drugs which have been very successful in lowering levels of LDL – or bad cholesterol.
Researchers have known for some time that when the protein PCSK9 (which stands for proprotein convertase subtilisin/kexin 9) binds to LDL receptors on the liver, compromising the organ’s ability to filter the bad cholesterol from the blood.
Too much LDL (bad) cholesterol circulating in the blood can lead to the thickening of artery walls, making them less flexible and therefore impairing their function and increasing the risk of heart disease.
In this phase one clinical trial, which is designed to determine if a drug is safe, researchers found that using a monoclonal antibody (lab-produced protein) called REGN727, was not only safe, but it also effectively blocked PCSK9 and therefore signficantly reduced bad cholesterol in healthy patients as well as those also taking the popular cholesterol-lowering drug Lipitor.
Earlier studies had shown this effect in primates, but this new study, published Wednesday in the New England Journal of Medicine, provides the first clinical trial data for testing the drug on humans. This new drug is being developed by Regeneron Pharmaceuticals and Sanofi, who funded the research.
“Wars for PCSK9 are far bigger than the statin wars, ” says Dr. Evan A Stein, of the Metabolic and Atherosclerosis Research Center in Cincinnati, Ohio. “This is a hot research area and everybody is so close together,” says Stein – the lead author of the study.
Other companies including Amgen, Merck & Company, Novartis and Pfizer, are also hot on the trail developing their own PCSK9 inhibitor drugs. Stein said.
Additional results for PCSK9 inhibitor drugs are expected to be presented at the annual American College of Cardiology meeting which begins Saturday in Chicago, he said.
The REGN727 study included three trial arms. Two arms used 72 healthy volunteers who were either injected with a single dose of the drug in increasing amounts to test for side effects, which is the purpose of a phase one clinical trial. A third arm included 21 people with a family history of high cholesterol, and 30 people with nonfamilial high cholesterol. All of those subjects were also receiving treatment with the statin Lipitor. A control group of subjects with nonfamilial high cholesterol was treated only with a special diet. None of the subjects who received REGN727 discontinued the study because of adverse effects, and the subjects who received REGN727 had a striking reduction of 60-65% in LDL cholesterol, according to Stein.
Stein characterized the results of the trial as “pretty dramatic.”
A PCSK9 inhibitor, Stein said, differs from statins “because it’s unlike any other drug. With statins you get toxicity — with these drugs we don’t see any side effects with the antibody.”
In an accompanying editorial, authors Dr. Stephen G. Young, and Loren G. Fong, Ph.D. write: “At this point, the status of PCSK9 therapeutics appears to be full speed ahead. Soon, we can expect more human trials in which investigators will dissect the properties of different PCSK9 antibodies and assess the effect of these agents.”
However, without long-term safety data and evidence that PCSK9 inhibitors truly help prevent heart disease, Young and Fong caution that it will remain unclear how important this class of drugs will be.
The cost of this drug will also play a role in determining which patients might use it, Fong and Young say. But they also note that “patients who cannot tolerate statins could benefit greatly.”
If the results are confirmed, “This is game changing science,” said Dr. Richard A. Stein, a spokesman for the American Heart Association who’s not related to the study author or involved in the research.
Stein called the trial results “a very important breakthrough,” while being careful to note that they represent early science which should be confirmed through larger and longer studies.
He said the study methodology was thorough because it included people with high cholesterol as well as people with genetic familial high cholesterol, which is proven to be a result of impaired PCSK9 genetic function.